Start Codon debuts companies from life science business acceleration programme

Start Codon, life science and healthcare business accelerator, has showcased its first cohort of start-ups. The company aims to minimise risk and translate early stage research into successful start-ups, ready for funding and partnership.

Start Codon has been working closely with four life science and healthcare companies that were enrolled into the programme in February this year. They are:

Enhanc3D Genomics, a functional genomics spin-out of the Babraham Institute (Cambridge, UK) whose platform technology links non-coding sequence variants to their target genes in order to identify novel therapeutic targets;

Drishti Discoveries, a start-up leveraging a proprietary gene silencing technology to develop therapies for rare inherited diseases;

Spirea, a spin-out from the University of Cambridge, who is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients;

Semarion, a University of Cambridge spin-out, revolutionising cell-based assays for drug discovery and life science through its proprietary SemaCyte microcarrier platform, which leverages novel materials physics for assay miniaturisation, multiplexing, and automation.

The companies will debut on 26 June 2020 at the Milner Therapeutics Symposium Building Collaborations to Transform Therapies, and 14 July during the annual OnHelix conference organised by One Nucleus. The presentations will see the companies unveiled to audiences of investors and senior pharma execs.

Start Codon plans to invest in and support up to 50 start-up companies over the next five years. The accelerator is now accepting applications for its second and third cohorts of companies. Early stage start-up companies in the life sciences and healthcare space are invited to apply.

Dr Jason Mellad, Co-founder and CEO at Start Codon (pictured), said: “We are providing life science and healthcare companies with a unique combination of funding, facilities and mentoring to support their development and success. It is exciting to be working closely with these four exciting start-up companies, helping them to successfully commercialise their novel ideas and discoveries.”

Daniel Rooke, Co-founder and Head of Operations and Legal at Start Codon, said: “We are extremely proud to present the first group of companies from the Start Codon programme. Having provided the mentoring, coaching and infrastructure to fast-track their commercial development, it is incredibly exciting to see how the technologies and teams have progressed.”

Image: Markus Spiske

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free